ArticleBlood neoplasia2025

Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapy.

Chathuri Abeyakoon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.